Boston Society Gene and Cell Therapy Conference
March 19 - 20, 2026
Bristol Myers Squibb, 250 Water Street, Cambridge, MA 02141
Confirmed Speakers 2026
We're continuing to build the 2026 program - check back soon for more speakers and updates.
 |
Prof. Mimoun Azzouz School of Medicine & Population Health, Chair of Translational Neuroscience, Director of GTIMC @ University of Sheffield, UK ARDAT workstreams and objectives - talk title TBA |
 |
Amy Rosenberg, PhD Senior Director Regulatory Affairs @ Regeneron Success of CAR-T Cells in Treatment of Autoimmunity: Broader Application to Disease Treatment & Prevention Including Immunogenicity of Therapeutic Proteins |
 |
Eva Andres-Mateos, PhD Associated VP Preclinical Development Gene Therapy @ Eli Lilly Translational sciences for GT/clinical data - talk title TBA |
 |
Brian Furmanski, PhD Chief Regulatory Officer @ Kriya Therapeutics IND submission/regulatory perspective - talk title TBA |
 |
Joleen White, PhD BioData Solutions Evaluating Immunogenicity in Cell and Gene Therapies |
 |
Aman Singh, PhD Group Director - Clinical Pharmacology & Pharmacometrics @ Johnson & Johnson SLE CAR-T modeling - talk title TAB
|
 |
Jim MacKrell, PhD Lilly Ventures - VP & Global Head of Science Team |
 |
Matt Silva, PhD CEO, EMIT Imaging Cryo-Fluorescence Tomography: Transformative 3D Imaging for Gene & Cell Therapy
|
2026 Proposed Sessions
Preclinical Approaches to GCT
Preclinical Discovery & Development
Safety Tox. Assessments (in vitro//in vivo tools/models)
IND Submission Processes
Regulatory Perspectives
Industry Landscape
Clinical Approaches to GCT
Clinical Pharmacology
Modeling & Simulation/QSP
Manufacturing/CMC
Commercialization/Post Manufacturing Commitments
Patient Perspective
Please Join our LinkedIn Group
